WebApr 18, 2024 · Pear is a leader in developing prescription digital therapeutics, developing the first FDA-cleared mobile medical application with both a safety and efficacy label to help treat patients with Substance Use Disorder in September 2024. Novartis invested in Pear's Series A and in its Series B rounds of financing. Indication: WebBut elsewhere, the company' Sandoz is pulling the plug on its commercialization partnership with Pear Therapeutics, ending its experiment with digital treatments for substance use disorders that ...
Novartis Terminates Pear Therapeutics Partnership
WebApr 18, 2024 · Pear’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia, for which Pear intends to obtain FDA clearance. WebMar 1, 2024 · Pear will work with Joris van Dam, Novartis’s executive director for digital therapeutics at the Novartis Institutes for BioMedical Research. John Carroll, with Endpoints News, writes, “Getting a heavyweight player in the biopharma industry to collaborate with five-year-old Pear is a big plus for digital medicine, where cognitive behavioral ... biometrics loop recorder
Global Digital Therapeutics Market 2024 [Latest Report
WebMar 2, 2024 · Novartis has partnered with US-based firm Pear Therapeutics for the development of new prescription software applications ‘digital therapeutics’ to help patients with schizophrenia and multiple sclerosis. Novartis headquarters in Basel, Switzerland. Credit: Novartis AG. WebMar 1, 2024 · Novartis has joined with one of the rising stars in digital health, Pear Therapeutics, to develop digital therapeutics for patients with schizophrenia and multiple sclerosis. The Swiss pharma ... WebNov 20, 2024 · Pear Therapeutics, Novartis announce commercial launch of reSET As the first prescription digital therapeutic approved by the FDA, the treatment will be distributed and supported by a specialist-staffed service center. By Dave Muoio November 20, 2024 03:35 pm Share daily success